Skip to content

Clinical trials

Observational Peanut Hypersensitivity trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Peanut Hypersensitivity Phase: Observational Clear all

30 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20061
20101
20111
20131
20141
20156
20163
20171
20183
20191
20201
20211
20221
20232
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed13
Unknown status5
Recruiting4
Terminated3
Active, not recruiting3
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)6
University Hospital, Montpellier3
Bühlmann Laboratories AG2
Lille Catholic University2
Luxembourg Institute of Health2
Massachusetts General Hospital2
Charite University, Berlin, Germany1
Dr. Anne Ellis1
Hamilton Health Sciences Corporation1
Johns Hopkins University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Peanut Hypersensitivity30
Food Hypersensitivity18
Hypersensitivity6
Nut Hypersensitivity5
Egg Hypersensitivity4
Milk Hypersensitivity4
Anaphylaxis3
Dermatitis, Atopic3
Eosinophilic Esophagitis2
Rhinitis, Allergic2

Trials

Showing 51 to 30 of 30. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.